loadpatents
name:-0.030771017074585
name:-0.019279003143311
name:-0.00054001808166504
Rennert; Paul D. Patent Filings

Rennert; Paul D.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Rennert; Paul D..The latest application filed is for "anti-tim-1 antibodies and uses thereof".

Company Profile
0.17.20
  • Rennert; Paul D. - Holliston MA
  • Rennert; Paul D. - Millis MA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
ANTI-TIM-1 Antibodies And Uses Thereof
App 20150110792 - Bailly; Veronique ;   et al.
2015-04-23
Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
Grant 8,287,874 - Browning , et al. October 16, 2
2012-10-16
Soluble Lymphotoxin-beta Receptors And Anti-lymphotoxin Receptor And Ligand Antibodies As Therapeutic Agents For The Treatment Of Immunological Diseases
App 20120156214 - BROWNING; Jeffrey L. ;   et al.
2012-06-21
Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
Grant 7,744,891 - Browning , et al. June 29, 2
2010-06-29
Kim-1 Antagonists And Use To Modulate Immune System
App 20100080798 - Rennert; Paul D.
2010-04-01
KIM-1 antagonists and use to modulate immune system
Grant 7,597,887 - Rennert October 6, 2
2009-10-06
Methods For Treating Hiv Infected Subjects
App 20090155836 - JUNE; Carl H. ;   et al.
2009-06-18
Methods for selectively enriching TH1 and TH2 cells
Grant 7,479,269 - June , et al. January 20, 2
2009-01-20
Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
App 20080219967 - Browning; Jeffrey L. ;   et al.
2008-09-11
Soluble lymphotoxin-.beta. receptors as therapeutic agents for the treatment of systemic lupus erythematosus
Grant 7,309,492 - Browning , et al. December 18, 2
2007-12-18
Use of lymphotoxin-.beta. receptor blocking agents for the treatment of antibody mediated immunological diseases
Grant 7,255,854 - Browning , et al. August 14, 2
2007-08-14
Methods for treating HIV infected subjects
Grant 7,232,566 - June , et al. June 19, 2
2007-06-19
Methods for selectively stimulating proliferation of T cells
Grant 7,175,843 - June , et al. February 13, 2
2007-02-13
Methods for selectively stimulating proliferation of T cells
Grant 7,144,575 - June , et al. December 5, 2
2006-12-05
Kim-1 antagonists and use to modulate immune system
App 20060222648 - Rennert; Paul D.
2006-10-05
Compositions comprising a first agent which provides a primary activation signal to T cells and a second agent which stimulates an accessory molecule on the surface of T cells
App 20060205069 - June; Carl H. ;   et al.
2006-09-14
Methods for selectively stimulating proliferation of T cells
App 20060140919 - June; Carl H. ;   et al.
2006-06-29
Methods for treating HIV infected subjects
App 20060099177 - June; Carl H. ;   et al.
2006-05-11
Methods for treating HIV infected subjects
App 20060013832 - June; Carl H. ;   et al.
2006-01-19
Methods for preparing highly active april ligand polypeptides
App 20060003407 - Rennert; Paul D. ;   et al.
2006-01-05
CTLA4-Cy4 fusion proteins
App 20050196402 - Gray, Gary S. ;   et al.
2005-09-08
Methods for selectively stimulating proliferation of T cells
Grant 6,905,681 - June , et al. June 14, 2
2005-06-14
Methods of treating HIV infected subjects
Grant 6,905,680 - June , et al. June 14, 2
2005-06-14
Methods for selectively stimulating proliferation of T cells
Grant 6,887,466 - June , et al. May 3, 2
2005-05-03
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies
App 20040202650 - Gribben, John G. ;   et al.
2004-10-14
CTLA-4 immunoglobulin fusion proteins having modified effector functions and uses therefor
App 20040151725 - Gray, Gary S. ;   et al.
2004-08-05
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
Grant 6,750,334 - Gray , et al. June 15, 2
2004-06-15
Methods for selectively stimulating proliferation of T cells
App 20040001829 - June, Carl H. ;   et al.
2004-01-01
Methods For Selectively Stimulating Proliferation Of T Cells
App 20030099643 - JUNE, CARL H. ;   et al.
2003-05-29
Methods for selectively stimulating proliferation of T cells
Grant 6,534,055 - June , et al. March 18, 2
2003-03-18
Soluble lymphotoxin beta receptor and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for treatment
App 20020197254 - Browning, Jeffrey L. ;   et al.
2002-12-26
CTLA4-C.gamma.4 fusion proteins
Grant 6,444,792 - Gray , et al. September 3, 2
2002-09-03
CTLA4-Cgamma4 fusion proteins
App 20020114814 - Gray, Gary S. ;   et al.
2002-08-22
Methods For Selectively Stimulating Proliferation Of T Cells
App 20020115214 - JUNE, CARL H. ;   et al.
2002-08-22
Method For Selectively Stimulating Proliferation Of T Cells
App 20020076407 - JUNE, CARL H. ;   et al.
2002-06-20
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
Grant 6,352,694 - June , et al. March 5, 2
2002-03-05
Methods for selectively stimulating proliferation of T cells
Grant 5,858,358 - June , et al. January 12, 1
1999-01-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed